Mapping the Cellular Drivers of Crohn's Disease

Precision medicine requires more than high-level observations; it requires a granular understanding of cellular behavior. Researchers from the Wellcome Sanger Institute, Cambridge University Hospitals NHS Foundation Trust (CUH), and Open Targets have developed a detailed study of Crohn’s disease (CD) that maps gene activity changes across more than 50 cell types in the gut via single-cell RNA-sequencing.

The team analyzed over a million gut cells from people with Crohn’s and healthy controls to identify the specific immune cells driving inflammation. This work produced IBDverse, a single cell RNA-sequencing (sc-RNA-seq) resource that characterizes each cell type and identifies those whose activity shifts during the disease. By uncovering new molecular and cellular signatures in the gut lining, this resource provides a foundation for identifying how inflammation begins and persists.

This level of resolution changes the trajectory of drug discovery. Open Targets, a pre-competitive, public-private partnership founded in 2014, uses human genetics and genomics data to prioritize drug targets. The IBDverse resource allows researchers to move past broad inflammatory markers toward targeted therapies that address specific cellular disruptions.

The implications for biotechnology are clear: the ability to pinpoint which cells drive disease activity creates immediate new avenues for drug development. As this research shows, understanding the biological disruption of gut and immune function is the prerequisite for developing more effective and safe medications. The existence of two complementary studies built on IBDverse—one recently published in Nature Genetics and another in Nature—suggests that the industry is already moving toward using this map to investigate different aspects of Crohn's pathogenesis.

The question for developers is no longer whether we can see the inflammation, but how precisely we can target the specific cell types identified in this map.